You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Eli Lilly to supply 400,000 tablets of its Covid-19 treatment to India

The country is fighting a raging pandemic that has morgues and hospitals overflowing.

Coronavirus | Coronavirus Vaccine | Coronavirus Tests


Photo: Bloomberg
Photo: Bloomberg

Eli Lilly and Co said on Tuesday it would supply 400,000 tablets of its COVID-19 treatment, to be used with Gilead's remdesivir, to the Indian government as the country fights a raging pandemic that has morgues and hospitals overflowing.

With 3.45 million active cases, India recorded 357,229 new infections over the last 24 hours, while deaths rose 3,449 for a toll of 222,408, health ministry data showed. Experts say actual numbers could be five to 10 times higher, however.

The drugmaker said it will work urgently to increase the supply multifold over the coming weeks.

On Monday, India's drug regulator gave emergency use approval to Lilly's treatment, baricitinib, for its use in hospitalized COVID-19 patients requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation.

The drug will be used in combination with Gilead Sciences's COVID-19 drug remdesivir.

Lilly is offering donations of its rheumatoid arthritis drug baricitinib for COVID-19 treatment to the Indian government through aid organization Direct Relief.


(Reporting by Dania Nadeem in Bengaluru; Editing by Shinjini Ganguli)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, May 04 2021. 17:51 IST